COPD Diagnosis and Management

Diagnostic Criteria

The European Respiratory Society recommends considering COPD in individuals with chronic respiratory symptoms and/or exposure to risk factors, and using pre-bronchodilator spirometry to rule out COPD and post-bronchodilator measurements to confirm the diagnosis, with a threshold of post-bronchodilator FEV1/FVC ratio <0.7 defining airflow obstruction 1, 2, 3
A detailed medical history should include exposure to risk factors, pattern of symptom development, history of exacerbations, and impact of disease on patient's life 3

Pre-bronchodilator spirometry is recommended as an initial test to investigate airflow obstruction, and post-bronchodilator spirometry with FEV1/FVC ratio <0.7 is required to confirm the diagnosis of COPD 1, 2, 4
Post-BD results close to the threshold should be repeated to ensure correct diagnosis 1

Volume responders, patients with significant gas trapping, may have pre-BD FEV1/FVC ≥0.7 but post-BD FEV1/FVC <0.7 due to greater improvement in FVC relative to FEV1 1, 5
Flow responders, patients with greater FEV1 improvement relative to FVC, may increase FEV1/FVC from <0.7 pre-BD to ≥0.7 post-BD, and require monitoring as they have increased likelihood of developing post-BD obstruction during follow-up 1

The GOLD criteria classify COPD severity based on FEV1 percentage predicted, with GOLD 1 (Mild): FEV1 ≥80% predicted, GOLD 2 (Moderate): FEV1 50-79% predicted, GOLD 3 (Severe): FEV1 30-49% predicted, and GOLD 4 (Very Severe): FEV1 <30% predicted 6, 7, 8

The European Respiratory Society recommends long-acting bronchodilator (either LAMA or LABA) as first-line therapy for symptomatic patients, and short-acting bronchodilators as rescue medication for symptom relief 6, 7, 8, 9
Inhaled corticosteroids (ICS) are recommended for patients with more severe disease or frequent exacerbations 6, 7

Follow-up should be scheduled in 4-6 weeks to assess response to therapy, inhaler technique, symptom control, and need for treatment adjustment, and annual spirometry is recommended to monitor disease progression 6, 7, 8, 9

Using pre-BD values alone would lead to a significant increase in the number of patients diagnosed with COPD, putting additional pressure on health services 1, 9
Spirometry quality is important, and ideally, grade A results should be obtained, but even grade E or grade U readings can be used for diagnostic purposes when carefully considered alongside clinical information 4, 9
Bronchodilator responsiveness testing has poor discriminative properties for differentiating COPD from asthma 10
CT scanning can provide information relevant to COPD diagnosis but availability and cost currently preclude routine use 9, 4